Here Comes Sun’s US Cost-Saving Gleevec Generic
This article was originally published in PharmAsia News
Executive Summary
India’s Sun Pharma has launched its generic version of Novartis' blockbuster anticancer Gleevec in the US at savings of around 30%, putting the spotlight on the specialty segment which is probably, for the first time, witnessing genericization of such a high cost therapy.